Enlivex Receives DKMA Approval for Allocetra Phase 2b Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ENLV?
Enlivex announced that it has received Clinical Trial Application, CTA, approval by the Danish Medicines Agency, DKMA, for the Phase 2b trial of Allocetra, the Company's clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, OA. The planned global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial, recently approved by the FDA, has been designed to evaluate the efficacy and safety of intra-articular injections of Allocetra in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The clinical trial is designed to enroll patients from clinical centers in the United States, Denmark and Poland.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENLV
Wall Street analysts forecast ENLV stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.878
Low
13.00
Averages
13.00
High
13.00
Current: 0.878
Low
13.00
Averages
13.00
High
13.00
About ENLV
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Enlivex Secures Danish Clinical Trial Approval for Allocetra™
- Clinical Trial Approval: Enlivex Ltd. has received approval from the Danish Medicines Agency to enroll patients for the Phase 2b trial of Allocetra™, marking a significant advancement in the company's global strategy.
- FDA Clearance Follow-Up: This approval follows the recent FDA clearance for the trial in the U.S., highlighting Allocetra™'s potential in treating moderate-to-severe knee osteoarthritis, which currently affects over 32 million Americans.
- Multicenter Trial Design: The trial will be conducted across multiple clinical centers in the U.S., Denmark, and Poland, aiming to evaluate the efficacy and safety of Allocetra™, particularly focusing on key endpoints related to pain relief and functional improvement.
- Strong Market Demand: Given the high prevalence of knee osteoarthritis worldwide, projected to impact 78 million Americans by 2040, Enlivex's research is set to provide much-needed treatment options in this area, presenting significant market potential.
See More
Enlivex Launches ENLVon Tokenized Shares on Ondo
- Tokenized Stock Launch: Enlivex Ltd. has launched ENLVon on the Ondo Global Markets platform, enabling non-U.S. retail and institutional investors to gain direct exposure to its ordinary shares through digital infrastructure, marking a significant innovation at the intersection of capital markets and blockchain.
- Market Share Leadership: Ondo has established itself as a leader in the tokenized stock market with over 61% market share, supporting approximately 265 tokenized securities and ETFs, showcasing its strong influence and growth potential in this emerging asset class.
- Lower Investment Barriers: The ENLVon model allows for fractional investments with low minimum amounts and near-instant settlement, thereby broadening accessibility for a global base of digitally native investors and facilitating wider access to traditional securities.
- Strategic Implications: Enlivex CEO Oren Hershkovitz emphasized that the launch of ENLVon not only enhances market visibility but also has the potential to attract more investors by increasing liquidity and trading flexibility, further advancing the company's clinical-stage immunotherapy development.
See More
Rain Foundation Launches $5 Million Grant Program for Prediction Markets
- Grant Program Launch: The Rain Foundation has announced a $5 million grant program aimed at supporting developers and creators worldwide in building, launching, and monetizing independent prediction markets through AI agents, which is expected to accelerate market innovation and drive industry growth.
- AI Agent Interface Release: The Rain Foundation has launched an AI agent-ready interface that allows developers using OpenClaw and other AI agents to generate live prediction markets via a single prompt, significantly lowering the technical barriers to market development and attracting more creative ideas into the market.
- Market Access Expansion: As interest in prediction markets continues to grow, the Rain Foundation is opening its protocol system to a broader group of developers, providing the necessary infrastructure for them to create and launch their own applications and prediction markets directly on the protocol, which is anticipated to enhance market activity.
- RAIN Token Potential: Enlivex CEO Oren Hershkovitz stated that the success of the Rain protocol will contribute to the value growth of the RAIN token, as approximately 2.5% of the total trading volume is expected to be allocated for automatic buy-and-burn of the RAIN token, thereby enhancing its scarcity and market appeal.
See More
Envilex Therapeutics Reports Strong FY Earnings
- Earnings Highlight: Envilex Therapeutics reported a FY GAAP EPS of $25.48, indicating strong growth in financial performance that reflects the effectiveness of its business model and increasing market demand.
- Cash Position: The company holds $30 million in cash, cash equivalents, and short-term investments in digital assets, providing a solid financial foundation for future R&D and market expansion initiatives.
- Market Rating: Seeking Alpha's Quant Rating on Envilex Therapeutics indicates a positive market outlook on its growth potential, further boosting investor confidence in the company's stock.
- Historical Financial Data: Historical earnings data for Envilex Therapeutics shows a continuous improvement in profitability, suggesting an increasing competitiveness in the biopharmaceutical sector that may attract more investor interest.
See More
Enlivex Reports Strong 2025 Earnings Driven by Treasury Asset Appreciation
- Net Income Surge: Enlivex reported a net income of $1.23 billion for 2025, with diluted earnings per share at $25.48, primarily driven by the appreciation of the company's treasury and treasury-related derivative assets, indicating strong financial management and profitability.
- Asset Allocation Strategy: The total treasury and treasury-related derivative assets reached $2.31 billion, with shareholders' equity at $1.93 billion, reflecting Enlivex's effective asset allocation, providing a solid financial foundation for future investments and R&D.
- Dual Strategy Advancement: Enlivex's dual strategy combines immunotherapy targeting the aging market with a treasury model based on the RAIN protocol, aiming to enhance the company's competitiveness in the longevity health sector through innovative therapeutic solutions and market infrastructure.
- Clinical Progress and Market Outlook: The company is advancing clinical trials for Allocetra™, aimed at improving the quality of life for aging populations, while establishing a prediction markets treasury to enhance investment appeal in emerging markets, signaling future growth potential.
See More
Enlivex Secures FDA Approval for Phase 2b Trial of Allocetra™
- FDA Approval: Enlivex has received FDA clearance to initiate a Phase 2b clinical trial for Allocetra™, targeting moderate-to-severe age-related knee osteoarthritis, marking a significant milestone in the company's clinical-stage quality longevity program aimed at improving the quality of life for elderly patients.
- Trial Design: The trial will be randomized, double-blind, and placebo-controlled, designed to evaluate Allocetra™'s efficacy in pain relief and physical function improvement, potentially offering new treatment options for over 32 million Americans suffering from this condition.
- Market Potential: Knee osteoarthritis is one of the most prevalent disabling diseases globally, projected to affect 78 million Americans by 2040, and Enlivex's treatment could fill a significant gap in the market where effective therapies are currently lacking, presenting substantial commercial opportunities.
- Dual-Engine Value Creation Model: This FDA approval represents the first success of Enlivex's dual-engine value creation model, which integrates clinical-stage quality longevity therapeutics with a prediction markets treasury strategy, showcasing the company's strategic advantage in innovation and market adaptability.
See More
Enlivex Secures Danish Clinical Trial Approval for Allocetra™
- Clinical Trial Approval: Enlivex Ltd. has received approval from the Danish Medicines Agency to enroll patients for the Phase 2b trial of Allocetra™, marking a significant advancement in the company's global strategy.
- FDA Clearance Follow-Up: This approval follows the recent FDA clearance for the trial in the U.S., highlighting Allocetra™'s potential in treating moderate-to-severe knee osteoarthritis, which currently affects over 32 million Americans.
- Multicenter Trial Design: The trial will be conducted across multiple clinical centers in the U.S., Denmark, and Poland, aiming to evaluate the efficacy and safety of Allocetra™, particularly focusing on key endpoints related to pain relief and functional improvement.
- Strong Market Demand: Given the high prevalence of knee osteoarthritis worldwide, projected to impact 78 million Americans by 2040, Enlivex's research is set to provide much-needed treatment options in this area, presenting significant market potential.
See More
Enlivex Launches ENLVon Tokenized Shares on Ondo
- Tokenized Stock Launch: Enlivex Ltd. has launched ENLVon on the Ondo Global Markets platform, enabling non-U.S. retail and institutional investors to gain direct exposure to its ordinary shares through digital infrastructure, marking a significant innovation at the intersection of capital markets and blockchain.
- Market Share Leadership: Ondo has established itself as a leader in the tokenized stock market with over 61% market share, supporting approximately 265 tokenized securities and ETFs, showcasing its strong influence and growth potential in this emerging asset class.
- Lower Investment Barriers: The ENLVon model allows for fractional investments with low minimum amounts and near-instant settlement, thereby broadening accessibility for a global base of digitally native investors and facilitating wider access to traditional securities.
- Strategic Implications: Enlivex CEO Oren Hershkovitz emphasized that the launch of ENLVon not only enhances market visibility but also has the potential to attract more investors by increasing liquidity and trading flexibility, further advancing the company's clinical-stage immunotherapy development.
See More
Rain Foundation Launches $5 Million Grant Program for Prediction Markets
- Grant Program Launch: The Rain Foundation has announced a $5 million grant program aimed at supporting developers and creators worldwide in building, launching, and monetizing independent prediction markets through AI agents, which is expected to accelerate market innovation and drive industry growth.
- AI Agent Interface Release: The Rain Foundation has launched an AI agent-ready interface that allows developers using OpenClaw and other AI agents to generate live prediction markets via a single prompt, significantly lowering the technical barriers to market development and attracting more creative ideas into the market.
- Market Access Expansion: As interest in prediction markets continues to grow, the Rain Foundation is opening its protocol system to a broader group of developers, providing the necessary infrastructure for them to create and launch their own applications and prediction markets directly on the protocol, which is anticipated to enhance market activity.
- RAIN Token Potential: Enlivex CEO Oren Hershkovitz stated that the success of the Rain protocol will contribute to the value growth of the RAIN token, as approximately 2.5% of the total trading volume is expected to be allocated for automatic buy-and-burn of the RAIN token, thereby enhancing its scarcity and market appeal.
See More
Envilex Therapeutics Reports Strong FY Earnings
- Earnings Highlight: Envilex Therapeutics reported a FY GAAP EPS of $25.48, indicating strong growth in financial performance that reflects the effectiveness of its business model and increasing market demand.
- Cash Position: The company holds $30 million in cash, cash equivalents, and short-term investments in digital assets, providing a solid financial foundation for future R&D and market expansion initiatives.
- Market Rating: Seeking Alpha's Quant Rating on Envilex Therapeutics indicates a positive market outlook on its growth potential, further boosting investor confidence in the company's stock.
- Historical Financial Data: Historical earnings data for Envilex Therapeutics shows a continuous improvement in profitability, suggesting an increasing competitiveness in the biopharmaceutical sector that may attract more investor interest.
See More
Enlivex Reports Strong 2025 Earnings Driven by Treasury Asset Appreciation
- Net Income Surge: Enlivex reported a net income of $1.23 billion for 2025, with diluted earnings per share at $25.48, primarily driven by the appreciation of the company's treasury and treasury-related derivative assets, indicating strong financial management and profitability.
- Asset Allocation Strategy: The total treasury and treasury-related derivative assets reached $2.31 billion, with shareholders' equity at $1.93 billion, reflecting Enlivex's effective asset allocation, providing a solid financial foundation for future investments and R&D.
- Dual Strategy Advancement: Enlivex's dual strategy combines immunotherapy targeting the aging market with a treasury model based on the RAIN protocol, aiming to enhance the company's competitiveness in the longevity health sector through innovative therapeutic solutions and market infrastructure.
- Clinical Progress and Market Outlook: The company is advancing clinical trials for Allocetra™, aimed at improving the quality of life for aging populations, while establishing a prediction markets treasury to enhance investment appeal in emerging markets, signaling future growth potential.
See More
Enlivex Secures FDA Approval for Phase 2b Trial of Allocetra™
- FDA Approval: Enlivex has received FDA clearance to initiate a Phase 2b clinical trial for Allocetra™, targeting moderate-to-severe age-related knee osteoarthritis, marking a significant milestone in the company's clinical-stage quality longevity program aimed at improving the quality of life for elderly patients.
- Trial Design: The trial will be randomized, double-blind, and placebo-controlled, designed to evaluate Allocetra™'s efficacy in pain relief and physical function improvement, potentially offering new treatment options for over 32 million Americans suffering from this condition.
- Market Potential: Knee osteoarthritis is one of the most prevalent disabling diseases globally, projected to affect 78 million Americans by 2040, and Enlivex's treatment could fill a significant gap in the market where effective therapies are currently lacking, presenting substantial commercial opportunities.
- Dual-Engine Value Creation Model: This FDA approval represents the first success of Enlivex's dual-engine value creation model, which integrates clinical-stage quality longevity therapeutics with a prediction markets treasury strategy, showcasing the company's strategic advantage in innovation and market adaptability.
See More
